Focused on Diseases of Malabsorption and Nutrient Metabolism

At Anagram, we are developing a pipeline of products that use the power of orally delivered enzymes as therapeutics to solve complex problems. We are leveraging our team’s decades of experience in gastrointestinal diseases and novel enzyme technologies to advance a pipeline of orally delivered enzyme products that have the potential to make a life-changing impact for people and their families living with rare diseases.

Malabsorption syndromes and nutrient metabolism disorders are a group of conditions caused by enzyme deficiencies or genetic mutations that prevent the body from properly metabolizing or absorbing certain fats, carbohydrates, simple sugars, proteins, vitamins, or other key nutrients. These conditions affect infants, children, and adults worldwide — both those born with congenital rare diseases and those who develop malabsorption syndromes as part of another illness.

From developing new therapies to engaging with patient communities, everything we do focuses on what matters most to those living with rare diseases.

gi-icon.svg

Significant GI Symptoms

Steatorrhea, constipation, nausea, abdominal pain, bloating, gas, diarrhea

weight-Icon.svg

Weight Loss and Growth Impediment

Weight loss, wasting and fatigue are common and pronounced; these symptoms are independent predictors of survival

fattyacid-icon.svg

Fatty Acid, Carbohydrate, and Protein Abnormalities

Play a central role in severity of symptoms and disease progression

morbidity-icon.svg

Increased Morbidity and Reduced QoL

Worsens clinical outcomes; adds to the overall costs of care and dramatic impact to quality of life

expectancy-icon.svg

Reduced Life-Expectancy

Directly impacts survival in rare disease, cancer and pancreatitis

vitamin-icon.svg

Metabolic Challenges

Increased inflammation, vitamin deficiencies, reduced bone mineral metabolism and ultimately organ failure

Malabsorption of macronutrients
leads to debilitating clinical consequences:

Anagram Therapeutics seeks to unlock breakthrough orally delivered enzyme therapeutics engineered for rare, life-threatening diseases.